PharVision Advisers’s Progressive PGR Stock Holding History

PharVision Advisers’s Portfolio PGR Stock Details PGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,061	Closed	-$242K	–	504
2025 Q4	$242K	Sell	1,061 -257	-19%	-$58K	0.12%	415
2025 Q3	$325K	Buy	+1,318	New	+$325K	0.18%	181
2025 Q2	–	Sell	-956	Closed	-$271K	–	388
2025 Q1	$271K	Buy	+956	New	+$250K	0.38%	115

Other funds holding PGR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

PharVision Advisers's PGR Position: Q1 2026 in Review

PharVision Advisers sold out of Progressive (PGR) in Q1 2026, closing a stake of 1,061 shares — an estimated $242K sold.

PharVision Advisers first reported a position in PGR in Q1 2025 and held it in 3 quarters. The position peaked at $325K in Q3 2025. 1,761 funds tracked by Wall St. Rank hold PGR as of Q1 2026.

PharVision Advisers reported no remaining Progressive position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 1,061 Progressive shares in Q1 2026, an estimated $242K.
PharVision Advisers first reported a position in Progressive in Q1 2025 and held it in 3 quarters.
PharVision Advisers's Progressive position peaked at $325K in Q3 2025.
1,761 funds tracked by Wall St. Rank held Progressive as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.